Skip Navigation


NDT Advance Access originally published online on September 27, 2006
Nephrology Dialysis Transplantation 2007 22(1):3-5; doi:10.1093/ndt/gfl561
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/1/3    most recent
gfl561v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kamper, A.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kamper, A.-L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

The importance of a correct evaluation of progression in studies on chronic kidney disease

Anne-Lise Kamper

Department of Nephrology, Rigshospitalet, University of Copenhagen, Denmark

Correspondence and offprint requests to: Anne-Lise Kamper, Department of Nephrology P2132, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Email: anne.lise.kamper@rh.dk

Keywords: chronic kidney disease; evaluation of progression; GFR

The first 10% of the full text of this article appears below.

When studying the effect of therapeutic interventions on the progression of chronic kidney disease (CKD), the most relevant end points are death and development of end-stage renal disease (ESRD). However, since the rate of progression is often rather slow, the effect parameter that is usually monitored is one of the markers of glomerular filtration rate (GFR). The gold standard for determination of GFR is the renal clearance of inulin, administered as a constant intravenous infusion. This method, however, is rarely used, mainly due to its time-consuming chemical assay procedure. Alternative methods are radiolabelled markers and creatinine, . . . [Full Text of this Article]



   The handling of GFR data
 
Sequential measurements of GFR with comparison of values between the study groups or with comparison of changes between groups
Sequential measurement of plasma creatinine with doubling of baseline plasma creatinine as an end point and comparison of number of patients reaching this end point
Sequential measurement of GFR with calculation of the individual linear slopes of the GFR vs time plot and comparison of slopes between the study groups

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
R. Hanratty, M. Chonchol, L. M. Dickinson, B. L. Beaty, R. O. Estacio, T. D. MacKenzie, L. P. Hurley, S. L. Linas, J. F. Steiner, and E. P. Havranek
Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension
Nephrol. Dial. Transplant., November 4, 2009; (2009) gfp534v1.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Evans, C. M. Fored, R. Bellocco, G. Fitzmaurice, J. P. Fryzek, J. K. McLaughlin, O. Nyren, and C.-G. Elinder
Acetaminophen, aspirin and progression of advanced chronic kidney disease
Nephrol. Dial. Transplant., June 1, 2009; 24(6): 1908 - 1918.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. J.L. Bakker, A. Alkhalaf, L. Tarnow, and G. Navis
Comment on: Wanic et al. (2008) Exclusion of Polymorphisms in Carnosinase Genes (CNDP1 and CNDP2) as a Cause of Diabetic Nephropathy in Type 1 Diabetes: Results of Large Case-Control and Follow-Up Studies: Diabetes 57:2547-2551, 2008
Diabetes, December 1, 2008; 57(12): e16 - e16.
[Full Text] [PDF]